병원약사회지

  • 자료실
  • 병원약사회지
[논문] Apixaban을 투여받는 비판막성 심방세동 환자에서 투여 용량에 따른 유효성 및 안전성 평가(Evaluation of Efficacy and Safety of Different Apixaban Dose
in Patients with Non-Valvular Atrial Fibrillation)
Date

2020년 Vol.37 No.02

Authors
김유경†, 안서현, 윤정이, 권은영, 황보신이(가톨릭대학교 서울성모병원 약제부)
Keyword
Apixaban, Under dosage, Atrial fibrillation, Stroke, Systemic embolism
Abstract

Background & Objective : Recommended dosage of apixaban for non-valvular atrial fibrillation is 5 mg b.i.d.. Reduced dosage 2.5 mg b.i.d. is recommended for patients meeting the dose reduction criteria. In clinical practice, low dosage of apixaban is frequently administered in patients not meeting the reduction criteria. We compared the efficacy and safety of apixaban between the dosage of 5 mg b.i.d. and 2.5 mg b.i.d. in patients recommended with 5 mg b.i.d..


Methods : This study included patients younger than age 80 not meeting the dosage reduction criteria. Patients were classified into Group A who took apixaban 5 mg b.i.d. and Group B who took 2.5 mg b.i.d.. The efficacy endpoint was the incidence of ischemic stroke and systemic embolism. The safety endpoint was the incidence of major and non-major bleeding events.


Results : Among the eligible 127 patients, 57 patients were in Group A and 70 were in Group B. The mean age of patients was older in Group B (age 68.1 vs 72.8 yrs, p<0.001). The estimated glomerular filtration rate was lower in Group B (65.2 mL/min) than Group A (74.1 mL/min) (p=0.016). Group B had more heart failure and hypertension and less thromboembolic history than Group A (p<0.05). Ischemic stroke and systemic embolism occurred in four cases (7%) in Group A and four cases (5.7%) in Group B (p>0.999). No major bleeding events occurred in both groups, and non-major bleeding occurred seven cases (12.3%) and eight cases (11.4%) (p=0.882).


Conclusion : Dosage of 2.5 mg b.i.d. lower than recommended was preferentially used in older patients, with lower renal function, heart failure, and hypertension or without thromboembolic history. Low dosage apixaban showed no difference in drug efficacy and safety. Through further studies, it is worth considering newer guidelines to review specific conditions such as renal function, underlying diseases, and thromboembolic history among the elderly.


Full-Text
200-208학술보고6김유경.pdf